hVIVO (LON:HVO) Trading Down 46.3% - Here's What Happened

hVIVO plc (LON:HVO - Get Free Report) shares traded down 46.3% during mid-day trading on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares were traded during trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Ratings Changes

Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a report on Friday.

hVIVO Trading Down 46.3%

The firm's fifty day moving average is GBX 16.16 and its two-hundred day moving average is GBX 18.13. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The firm has a market cap of £61.56 million, a P/E ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts predict that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insider Transactions at hVIVO

In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,459.93). 14.03% of the stock is owned by insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.